• 1. Department of Radiation Physics and Technology Center, West China Hospital;
  • 2. College of Physical Sicence and Technology;Sichuan University, Chengdu, Sichuan 610041, P. R. China;
BAISen, Email: baisen@scu.edu.cn
Export PDF Favorites Scan Get Citation

Objective Compare the two-degrade collimator (MLC) angle selection's impact on plan quality and operational efficiency for volumetric intensity-modulated radiotherapy (VMAT) in the treatment planning system, and to explore the scheme for treatment plan optimization. Methods Twenty patients with nasopharyngeal carcinoma underwent the treatment between March and December 2013 were randomly selected and planned for SIBVMAT treatment with different parameters set in the range of 0-60°with 15°interval for collimator angles. Planned dose distribution to the target volumes, organs at risk, and monitor units were compared. Results As the MLC angle increased, target conformal index and homogeneity index had a trend to became deteriorated. The optimal plans were 0°and 15°, while 45°and 60°plans gave poor protection for the organ at risk compare to other angle plans and the monitor units were significantly increased. Conclusion Change the MLC angle had visible impact on treatment plans,there was a trend to deteriorate with the MLC angle increased, but small changes in MLC angle range can theoretically reduce the influence from leakage radiation on the human body.

Citation: JIChuan-xian, BAISen, LIGuang-jun, JIANGXiao-qin, XIAOJiang-hong. Application of Liner-accelerator Two-degrade Collimator in the Treatment of Nasopharyngeal Carcinoma with Volumetric Modulated Arc Therapy. West China Medical Journal, 2015, 30(7): 1235-1238. doi: 10.7507/1002-0179.20150355 Copy

Copyright © the editorial department of West China Medical Journal of West China Medical Publisher. All rights reserved

  • Previous Article

    Factors Associated with Complications in Patients with Pheochromocytoma:A Retrospective Analysis
  • Next Article

    Clinical Effcacy of Multipoint Injection of Botulinum Toxin in the Treatment of Spastic Cerebral Palsy in Children